Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
PRO data support the use of antibody–drug conjugates in metastatic breast cancer
Patient-reported data from the DESTINY-BREAST04 and TROPiCS-02 trials may help improve current knowledge of quality of life on long-term treatment
Lack of clinical benefit with adjuvant canakinumab in completely resected NSCLC
Negative results from the CANOPY-A trial do not support use in the adjuvant setting
First positive phase III data for a gamma secretase inhibitor in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
TILs confirm to prolong PFS compared with immunotherapy in advanced melanoma
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
A pathway from air pollution to lung cancer in non-smokers has been identified
In a study presented at ESMO Congress 2022, air pollution is shown to drive interleukin-1β release in cells with EGFR mutations to promote lung cancer development
Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Durvalumab plus cisplatin/gemcitabine is now standard of care for patients with advanced/metastatic biliary tract cancer
Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine
Second-line chemotherapy for advanced biliary tract provides modest efficacy but quality of life benefit
Standard second-line chemotherapy may benefit fit patients but efficacy is limited and new treatments are urgently needed
Final data from monarcHER suggest the utility of triple therapy over standard of care chemotherapy
Numerically improved overall survival was shown with abemaciclib plus trastuzumab and fulvestrant in patients with advanced breast cancer